When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. ‘Major breakthrough’ as dementia drug found to ‘slow ...

   www.aol.com/major-breakthrough-dementia-drug...

   A dementia charity has hailed a “historic moment” in Alzheimer’s research as a new drug has been found to reduce memory decline among patients with early-stage disease.

3. Everything we know about breakthrough Alzheimer’s ... - AOL

   www.aol.com/everything-know-breakthrough...

   The study, published in the Journal of the American Medical Association, concluded that after 76 weeks of treatment, Donanemab was able to slow clinical decline by 35.1% in people with early ...

4. New Research Offers Hope in the Fight Against Alzheimer’s - AOL

   www.aol.com/lifestyle/research-offers-hope-fight...

   Dementia is an umbrella term that describes a wide range of symptoms, including declines in memory, judgement, reasoning, and focus, as well as changes in language and behavior. ... Breakthroughs ...

5. Verubecestat - Wikipedia

   en.wikipedia.org/wiki/Verubecestat

   [9] [10] The final conclusion was that "verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer’s disease and was associated with treatment-related adverse events". Verubecestat was projected to be a breakthrough medicine for dementia related illness, however it is still unknown why the medicine ...

6. Solanezumab - Wikipedia

   en.wikipedia.org/wiki/Solanezumab

   Solanezumab was safely used in combination with approved Alzheimer's disease treatment, such as acetylcholinesterase inhibitors or memantine, in the clinical trials. [1] [7] [8] Aside from Alzheimer's disease, there are other amyloid beta related diseases, in which solanezumab could be used, e.g., Down syndrome or cerebral amyloid angiopathy. [9]

7. Breakthrough Alzheimer’s drug could be in UK use in a year ...

   www.aol.com/breakthrough-alzheimer-drug-could-uk...

   Patients could be getting breakthrough Alzheimer’s drug in a year, experts have said, but only a small proportion of patients will benefit unless more is done to boost dementia services in the NHS.